Weight-Loss Injections Linked to Gallbladder Risks: A Woman’s Terrifying Ordeal at Sea A woman’s cruise to the Virgin Islands turned into a nightmare when she suffered severe gallbladder inflammation, potentially linked to her use of weight-loss injections. Her story highlights the growing concerns over GLP-1 drugs like Mounjaro, Wegovy, and Ozempic, as medical professionals report a rise in gallbladder complications among users. With NHS data showing a surge in surgeries, the risks of rapid weight loss and slowed gallbladder function are under scrutiny. Last October, during a dream cruise to the Virgin Islands, Lynn Carratt awoke in excruciating pain, convinced she was suffering a heart attack. Sweating and panicking miles from land, she rushed to the ship’s medical center, where the doctor diagnosed her with an inflamed gallbladder after she screamed in agony upon examination. The thought of a potential rupture—fatal if untreated—terrified her, especially knowing she was far from medical help in the Caribbean. The prospect of leaving her four-year-old daughter without a mother was unbearable. Worse, she suspected her condition was linked to her use of weight-loss injections, a concern later validated by a gastroenterologist in London. Like 1.6 million others in the UK, she had been using GLP-1 receptor agonists such as Mounjaro, Wegovy, or Ozempic.Surgeon Ahmed Ahmed, president of the British Obesity and Metabolic Specialist Society, noted a rising trend of gallbladder surgeries among patients using these drugs, with Eli Lilly even listing gallbladder infection as a rare side effect. NHS data from 2024-2025 showed a decade-high peak in gallbladder surgeries, coinciding with the surge in popularity of these 'fat jabs.' The risk stems from GLP-1s slowing gallbladder emptying, while rapid weight loss causes the liver to release excess cholesterol into bile, increasing gallstone formation. After her diagnosis, Carratt endured sleepless nights, dreading the days until she could reach a hospital for a scan. She reflected on her decision to use Mounjaro, a choice driven by years of weight struggles and health warnings.At 43, with a BMI of 37, she had sought help at a local pharmacy, hoping the injections would finally solve her weight issues. Her history of yo-yo dieting, exacerbated by postpartum weight gain and poor eating habits, had led to fatty liver disease and metabolic syndrome—conditions reversible through weight loss. Though she researched side effects like nausea and pancreatitis, gallbladder issues were never mentioned.Her journey was grueling: initial nausea, vomiting, and stomach pain gave way to exhaustion as she increased her dose. Despite losing a stone in two months, the physical toll was severe, culminating in her terrifying ordeal at sea